Selected research
Market Outlook & Growth Opportunities
Global Neuromyelitis Optica Therapy Market Outlook and Growth Opportunities 2026
Market perspective
The global Neuromyelitis Optica Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Neuromyelitis Optica Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Neuromyelitis Optica Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Neuromyelitis Optica Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Neuromyelitis Optica Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Neuromyelitis Optica Therapy market include CBOP, CSL, Fresenius, Grifols, Gyjtrs, Intas, NANG KUANG, Octapharma and Tianjin Kingyork, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Neuromyelitis Optica Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Neuromyelitis Optica Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Neuromyelitis Optica Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Neuromyelitis Optica Therapy market.
Neuromyelitis Optica Therapy Segment by Company
CBOP
CSL
Fresenius
Grifols
Gyjtrs
Intas
NANG KUANG
Octapharma
Tianjin Kingyork
Baxter
Pfizer
Sandoz
Teva
Neuromyelitis Optica Therapy Segment by Type
Glucocorticoids
Immunotherapies
Other
Neuromyelitis Optica Therapy Segment by Application
Acute Attack
Remission Prophylactic Treatment
Neuromyelitis Optica Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Neuromyelitis Optica Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Neuromyelitis Optica Therapy key companies, revenue, market share, and recent developments.
3. To split the Neuromyelitis Optica Therapy breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Neuromyelitis Optica Therapy market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Neuromyelitis Optica Therapy significant trends, drivers, influence factors in global and regions.
6. To analyze Neuromyelitis Optica Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuromyelitis Optica Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuromyelitis Optica Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuromyelitis Optica Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuromyelitis Optica Therapy industry.
Chapter 3: Detailed analysis of Neuromyelitis Optica Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Neuromyelitis Optica Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Neuromyelitis Optica Therapy in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Neuromyelitis Optica Therapy Industry Trends
Table 2. Neuromyelitis Optica Therapy Industry Drivers
Table 3. Neuromyelitis Optica Therapy Industry Opportunities and Challenges
Table 4. Neuromyelitis Optica Therapy Industry Restraints
Table 5. Global Neuromyelitis Optica Therapy Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Neuromyelitis Optica Therapy Revenue Share by Company (2021-2026)
Table 7. Global Neuromyelitis Optica Therapy Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Neuromyelitis Optica Therapy Key Company Manufacturing Base & Headquarters
Table 9. Global Neuromyelitis Optica Therapy Company, Product Type & Application
Table 10. Global Neuromyelitis Optica Therapy Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Neuromyelitis Optica Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of Glucocorticoids
Table 15. Significant Companies of Immunotherapies
Table 16. Significant Companies of Other
Table 17. Global Neuromyelitis Optica Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 18. Global Neuromyelitis Optica Therapy Sales Value by Type (2021-2026) & (US$ Million)
Table 19. Global Neuromyelitis Optica Therapy Sales Value by Type (2027-2032) & (US$ Million)
Table 20. Global Neuromyelitis Optica Therapy Sales Value Share by Type (2021-2026)
Table 21. Global Neuromyelitis Optica Therapy Sales Value Share by Type (2027-2032)
Table 22. Significant Companies of Acute Attack
Table 23. Significant Companies of Remission Prophylactic Treatment
Table 24. Global Neuromyelitis Optica Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 25. Global Neuromyelitis Optica Therapy Sales Value by Application (2021-2026) & (US$ Million)
Table 26. Global Neuromyelitis Optica Therapy Sales Value by Application (2027-2032) & (US$ Million)
Table 27. Global Neuromyelitis Optica Therapy Sales Value Share by Application (2021-2026)
Table 28. Global Neuromyelitis Optica Therapy Sales Value Share by Application (2027-2032)
Table 29. Global Neuromyelitis Optica Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 30. Global Neuromyelitis Optica Therapy Sales Value by Region (2021-2026) & (US$ Million)
Table 31. Global Neuromyelitis Optica Therapy Sales Value Share by Region (2021-2026)
Table 32. Global Neuromyelitis Optica Therapy Sales Value by Region (2027-2032) & (US$ Million)
Table 33. Global Neuromyelitis Optica Therapy Sales Value Share by Region (2027-2032)
Table 34. Global Neuromyelitis Optica Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 35. Global Neuromyelitis Optica Therapy Sales Value by Country (2021-2026) & (US$ Million)
Table 36. Global Neuromyelitis Optica Therapy Sales Value Market Share by Country (2021-2026)
Table 37. Global Neuromyelitis Optica Therapy Sales Value by Country (2027-2032) & (US$ Million)
Table 38. Global Neuromyelitis Optica Therapy Sales Value Market Share by Country (2027-2032)
Table 39. CBOP Company Information
Table 40. CBOP Business Overview
Table 41. CBOP Neuromyelitis Optica Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 42. CBOP Neuromyelitis Optica Therapy Product Portfolio
Table 43. CBOP Recent Development
Table 44. CSL Company Information
Table 45. CSL Business Overview
Table 46. CSL Neuromyelitis Optica Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 47. CSL Neuromyelitis Optica Therapy Product Portfolio
Table 48. CSL Recent Development
Table 49. Fresenius Company Information
Table 50. Fresenius Business Overview
Table 51. Fresenius Neuromyelitis Optica Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 52. Fresenius Neuromyelitis Optica Therapy Product Portfolio
Table 53. Fresenius Recent Development
Table 54. Grifols Company Information
Table 55. Grifols Business Overview
Table 56. Grifols Neuromyelitis Optica Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 57. Grifols Neuromyelitis Optica Therapy Product Portfolio
Table 58. Grifols Recent Development
Table 59. Gyjtrs Company Information
Table 60. Gyjtrs Business Overview
Table 61. Gyjtrs Neuromyelitis Optica Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Gyjtrs Neuromyelitis Optica Therapy Product Portfolio
Table 63. Gyjtrs Recent Development
Table 64. Intas Company Information
Table 65. Intas Business Overview
Table 66. Intas Neuromyelitis Optica Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 67. Intas Neuromyelitis Optica Therapy Product Portfolio
Table 68. Intas Recent Development
Table 69. NANG KUANG Company Information
Table 70. NANG KUANG Business Overview
Table 71. NANG KUANG Neuromyelitis Optica Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 72. NANG KUANG Neuromyelitis Optica Therapy Product Portfolio
Table 73. NANG KUANG Recent Development
Table 74. Octapharma Company Information
Table 75. Octapharma Business Overview
Table 76. Octapharma Neuromyelitis Optica Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 77. Octapharma Neuromyelitis Optica Therapy Product Portfolio
Table 78. Octapharma Recent Development
Table 79. Tianjin Kingyork Company Information
Table 80. Tianjin Kingyork Business Overview
Table 81. Tianjin Kingyork Neuromyelitis Optica Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 82. Tianjin Kingyork Neuromyelitis Optica Therapy Product Portfolio
Table 83. Tianjin Kingyork Recent Development
Table 84. Baxter Company Information
Table 85. Baxter Business Overview
Table 86. Baxter Neuromyelitis Optica Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 87. Baxter Neuromyelitis Optica Therapy Product Portfolio
Table 88. Baxter Recent Development
Table 89. Pfizer Company Information
Table 90. Pfizer Business Overview
Table 91. Pfizer Neuromyelitis Optica Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Pfizer Neuromyelitis Optica Therapy Product Portfolio
Table 93. Pfizer Recent Development
Table 94. Sandoz Company Information
Table 95. Sandoz Business Overview
Table 96. Sandoz Neuromyelitis Optica Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Sandoz Neuromyelitis Optica Therapy Product Portfolio
Table 98. Sandoz Recent Development
Table 99. Teva Company Information
Table 100. Teva Business Overview
Table 101. Teva Neuromyelitis Optica Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Teva Neuromyelitis Optica Therapy Product Portfolio
Table 103. Teva Recent Development
Table 104. Research Programs/Design for This Report
Table 105. Authors List of This Report
Table 106. Secondary Sources
Table 107. Primary Sources
List of Figures
Figure 1. Neuromyelitis Optica Therapy Product Image
Figure 2. Global Neuromyelitis Optica Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million)
Figure 4. Global Neuromyelitis Optica Therapy Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. Glucocorticoids Image
Figure 8. Immunotherapies Image
Figure 9. Other Image
Figure 10. Global Neuromyelitis Optica Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 11. Global Neuromyelitis Optica Therapy Sales Value Share 2021 VS 2025 VS 2032
Figure 12. Global Neuromyelitis Optica Therapy Sales Value Share by Type (2021-2032)
Figure 13. Acute Attack Image
Figure 14. Remission Prophylactic Treatment Image
Figure 15. Global Neuromyelitis Optica Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 16. Global Neuromyelitis Optica Therapy Sales Value Share 2021 VS 2025 VS 2032
Figure 17. Global Neuromyelitis Optica Therapy Sales Value Share by Application (2021-2032)
Figure 18. Global Neuromyelitis Optica Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 19. Global Neuromyelitis Optica Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 20. North America Neuromyelitis Optica Therapy Sales Value (2021-2032) & (US$ Million)
Figure 21. North America Neuromyelitis Optica Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 22. Europe Neuromyelitis Optica Therapy Sales Value (2021-2032) & (US$ Million)
Figure 23. Europe Neuromyelitis Optica Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 24. Asia-Pacific Neuromyelitis Optica Therapy Sales Value (2021-2032) & (US$ Million)
Figure 25. Asia-Pacific Neuromyelitis Optica Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 26. South America Neuromyelitis Optica Therapy Sales Value (2021-2032) & (US$ Million)
Figure 27. South America Neuromyelitis Optica Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 28. Middle East & Africa Neuromyelitis Optica Therapy Sales Value (2021-2032) & (US$ Million)
Figure 29. Middle East & Africa Neuromyelitis Optica Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 30. USA Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 31. USA Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 32. USA Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 33. Canada Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 34. Canada Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 35. Canada Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 36. Mexico Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 37. Mexico Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 38. Mexico Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 39. Germany Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 40. Germany Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 41. Germany Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 42. France Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 43. France Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 44. France Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 45. U.K. Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 46. U.K. Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 47. U.K. Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 48. Italy Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 49. Italy Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 50. Italy Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 51. Spain Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 52. Spain Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 53. Spain Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 54. Russia Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 55. Russia Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 56. Russia Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 57. Netherlands Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 58. Netherlands Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 59. Netherlands Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 60. Nordic Countries Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 61. Nordic Countries Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 62. Nordic Countries Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 63. China Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 64. China Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 65. China Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 66. Japan Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 67. Japan Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 68. Japan Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 69. South Korea Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 70. South Korea Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 71. South Korea Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 72. India Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 73. India Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 74. India Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 75. Australia Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 76. Australia Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 77. Australia Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 78. Southeast Asia Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 79. Southeast Asia Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 80. Southeast Asia Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 81. Brazil Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 82. Brazil Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 83. Brazil Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 84. Argentina Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 85. Argentina Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 86. Argentina Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 87. Chile Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 88. Chile Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 89. Chile Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 90. Colombia Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 91. Colombia Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 92. Colombia Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 93. Peru Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 94. Peru Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 95. Peru Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 96. Saudi Arabia Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 97. Saudi Arabia Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 98. Saudi Arabia Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 99. Israel Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 100. Israel Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 101. Israel Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 102. UAE Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 103. UAE Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 104. UAE Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 105. Turkey Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 106. Turkey Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 107. Turkey Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 108. Iran Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 109. Iran Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 110. Iran Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 111. Egypt Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 112. Egypt Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 113. Egypt Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 114. Years Considered
Figure 115. Research Process
Figure 116. Key Executives Interviewed
Scope & coverage.
Types
- Glucocorticoids
- Immunotherapies
- Other
Applications
- Acute Attack
- Remission Prophylactic Treatment
Companies covered
- CBOP
- CSL
- Fresenius
- Grifols
- Gyjtrs
- Intas
- NANG KUANG
- Octapharma
- Tianjin Kingyork
- Baxter
- Pfizer
- Sandoz
- Teva
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Neuromyelitis Optica Therapy Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Neuromyelitis Optica Therapy Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Neuromyelitis Optica Therapy Market Dynamics
- 2.1 Neuromyelitis Optica Therapy Industry Trends
- 2.2 Neuromyelitis Optica Therapy Industry Drivers
- 2.3 Neuromyelitis Optica Therapy Industry Opportunities and Challenges
- 2.4 Neuromyelitis Optica Therapy Industry Restraints
3 Neuromyelitis Optica Therapy Market by Company
- 3.1 Global Neuromyelitis Optica Therapy Company Revenue Ranking in 2025
- 3.2 Global Neuromyelitis Optica Therapy Revenue by Company (2021-2026)
- 3.3 Global Neuromyelitis Optica Therapy Company Ranking (2024-2026)
- 3.4 Global Neuromyelitis Optica Therapy Company Manufacturing Base and Headquarters
- 3.5 Global Neuromyelitis Optica Therapy Company Product Type and Application
- 3.6 Global Neuromyelitis Optica Therapy Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Neuromyelitis Optica Therapy Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Neuromyelitis Optica Therapy Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Neuromyelitis Optica Therapy Market by Type
- 4.1 Neuromyelitis Optica Therapy Type Introduction
- 4.1.1 Glucocorticoids
- 4.1.2 Immunotherapies
- 4.1.3 Other
- 4.2 Global Neuromyelitis Optica Therapy Sales Value by Type
- 4.2.1 Global Neuromyelitis Optica Therapy Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Neuromyelitis Optica Therapy Sales Value by Type (2021-2032)
- 4.2.3 Global Neuromyelitis Optica Therapy Sales Value Share by Type (2021-2032)
5 Neuromyelitis Optica Therapy Market by Application
- 5.1 Neuromyelitis Optica Therapy Application Introduction
- 5.1.1 Acute Attack
- 5.1.2 Remission Prophylactic Treatment
- 5.2 Global Neuromyelitis Optica Therapy Sales Value by Application
- 5.2.1 Global Neuromyelitis Optica Therapy Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Neuromyelitis Optica Therapy Sales Value by Application (2021-2032)
- 5.2.3 Global Neuromyelitis Optica Therapy Sales Value Share by Application (2021-2032)
6 Neuromyelitis Optica Therapy Regional Value Analysis
- 6.1 Global Neuromyelitis Optica Therapy Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Neuromyelitis Optica Therapy Sales Value by Region (2021-2032)
- 6.2.1 Global Neuromyelitis Optica Therapy Sales Value by Region: 2021-2026
- 6.2.2 Global Neuromyelitis Optica Therapy Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Neuromyelitis Optica Therapy Sales Value (2021-2032)
- 6.3.2 North America Neuromyelitis Optica Therapy Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Neuromyelitis Optica Therapy Sales Value (2021-2032)
- 6.4.2 Europe Neuromyelitis Optica Therapy Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Neuromyelitis Optica Therapy Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Neuromyelitis Optica Therapy Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Neuromyelitis Optica Therapy Sales Value (2021-2032)
- 6.6.2 South America Neuromyelitis Optica Therapy Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Neuromyelitis Optica Therapy Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Neuromyelitis Optica Therapy Sales Value Share by Country, 2025 VS 2032
7 Neuromyelitis Optica Therapy Country-level Value Analysis
- 7.1 Global Neuromyelitis Optica Therapy Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Neuromyelitis Optica Therapy Sales Value by Country (2021-2032)
- 7.2.1 Global Neuromyelitis Optica Therapy Sales Value by Country (2021-2026)
- 7.2.2 Global Neuromyelitis Optica Therapy Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.7.2 France Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.14.2 China Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.17.2 India Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Neuromyelitis Optica Therapy Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Neuromyelitis Optica Therapy Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Neuromyelitis Optica Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 CBOP
- 8.1.1 CBOP Company Information
- 8.1.2 CBOP Business Overview
- 8.1.3 CBOP Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
- 8.1.4 CBOP Neuromyelitis Optica Therapy Product Portfolio
- 8.1.5 CBOP Recent Developments
- 8.2 CSL
- 8.2.1 CSL Company Information
- 8.2.2 CSL Business Overview
- 8.2.3 CSL Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
- 8.2.4 CSL Neuromyelitis Optica Therapy Product Portfolio
- 8.2.5 CSL Recent Developments
- 8.3 Fresenius
- 8.3.1 Fresenius Company Information
- 8.3.2 Fresenius Business Overview
- 8.3.3 Fresenius Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
- 8.3.4 Fresenius Neuromyelitis Optica Therapy Product Portfolio
- 8.3.5 Fresenius Recent Developments
- 8.4 Grifols
- 8.4.1 Grifols Company Information
- 8.4.2 Grifols Business Overview
- 8.4.3 Grifols Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
- 8.4.4 Grifols Neuromyelitis Optica Therapy Product Portfolio
- 8.4.5 Grifols Recent Developments
- 8.5 Gyjtrs
- 8.5.1 Gyjtrs Company Information
- 8.5.2 Gyjtrs Business Overview
- 8.5.3 Gyjtrs Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
- 8.5.4 Gyjtrs Neuromyelitis Optica Therapy Product Portfolio
- 8.5.5 Gyjtrs Recent Developments
- 8.6 Intas
- 8.6.1 Intas Company Information
- 8.6.2 Intas Business Overview
- 8.6.3 Intas Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
- 8.6.4 Intas Neuromyelitis Optica Therapy Product Portfolio
- 8.6.5 Intas Recent Developments
- 8.7 NANG KUANG
- 8.7.1 NANG KUANG Company Information
- 8.7.2 NANG KUANG Business Overview
- 8.7.3 NANG KUANG Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
- 8.7.4 NANG KUANG Neuromyelitis Optica Therapy Product Portfolio
- 8.7.5 NANG KUANG Recent Developments
- 8.8 Octapharma
- 8.8.1 Octapharma Company Information
- 8.8.2 Octapharma Business Overview
- 8.8.3 Octapharma Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
- 8.8.4 Octapharma Neuromyelitis Optica Therapy Product Portfolio
- 8.8.5 Octapharma Recent Developments
- 8.9 Tianjin Kingyork
- 8.9.1 Tianjin Kingyork Company Information
- 8.9.2 Tianjin Kingyork Business Overview
- 8.9.3 Tianjin Kingyork Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
- 8.9.4 Tianjin Kingyork Neuromyelitis Optica Therapy Product Portfolio
- 8.9.5 Tianjin Kingyork Recent Developments
- 8.10 Baxter
- 8.10.1 Baxter Company Information
- 8.10.2 Baxter Business Overview
- 8.10.3 Baxter Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
- 8.10.4 Baxter Neuromyelitis Optica Therapy Product Portfolio
- 8.10.5 Baxter Recent Developments
- 8.11 Pfizer
- 8.11.1 Pfizer Company Information
- 8.11.2 Pfizer Business Overview
- 8.11.3 Pfizer Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
- 8.11.4 Pfizer Neuromyelitis Optica Therapy Product Portfolio
- 8.11.5 Pfizer Recent Developments
- 8.12 Sandoz
- 8.12.1 Sandoz Company Information
- 8.12.2 Sandoz Business Overview
- 8.12.3 Sandoz Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
- 8.12.4 Sandoz Neuromyelitis Optica Therapy Product Portfolio
- 8.12.5 Sandoz Recent Developments
- 8.13 Teva
- 8.13.1 Teva Company Information
- 8.13.2 Teva Business Overview
- 8.13.3 Teva Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
- 8.13.4 Teva Neuromyelitis Optica Therapy Product Portfolio
- 8.13.5 Teva Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst